CoChat
Sign Up
Cited by 14

The DOI matches its Crossref record.

MT1-MMP silencing by an shRNA-armed glioma-targeted conditionally replicative adenovirus (CRAd) improves its anti-glioma efficacy in vitro and in vivo

Ulasov, Ilya, Borovjagin, Anton V., Kaverina, Natalya, Schroeder, Brett, Shah, Nameeta, Lin, Biaoyang, Baryshnikov, Anatoly, Cobbs, Charles·2015·Cancer Letters
DOI 10.1016/j.canlet.2015.06.002
Open this paper in CoChat — free account

Abstract

MMP14 (MT1-MMP) is a cell membrane-associated proteinase of the extracellular matrix, whose biological roles vary from angiogenesis to cell proliferation and survival. We recently found a direct correlation between MMP14 expression levels in brain tumors of glioma patients and the disease progression. By using gene silencing as an experimental approach we found that MMP14 knockdown decreases production of pro-angiogenic factors such as VEGF and IL8 and thereby suppresses angiogenesis in glioma tumors. Although the clinical relevance of MMP14 down-regulation and its possible implications for glioma therapy in humans remain unclear, we observed a significant improvement in animal survival upon down-regulation of MMP14 in murine intracranial glioma xenografts infected with MMP14 shRNA-expressing CRAd. We further found that down-regulation of MMP14 in gliomas by combinational treatment with CRAd-S-5/3 and Marimastat, a chemical inhibitor of metalloproteinases, augments suppression of pro-angiogenic factors, caused by the replication-competent adenovirus. We also demonstrated that delivery of MMP14-targeting shRNA by a fiber-modified adenoviral vector to the glioma cells effectively suppresses their proliferation in vitro and in vivo. Thus our data indicate that inhibition of MMP14 expression in tumors in combination with glioma virotherapy could be effectively utilized to suppress angiogenesis and neovascularization of glioma tumors by decreasing production of pro-angiogenic fact…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.canlet.2015.06.002

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 45

  1. Ulasov, 2006, CD46 represents a target for adenoviral gene therapy of malignant glioma, Hum. Gene Ther, 17, 556, 10.1089/hum.2006.17.556 · DOI
  2. Stupp, 2005, The role of radio- and chemotherapy in glioblastoma, Onkologie, 28, 315, 10.1159/000085575 · DOI
  3. Dey, 2010, Virotherapy against malignant glioma stem cells, Cancer Lett, 289, 1, 10.1016/j.canlet.2009.04.045 · DOI
  4. Bjorklund, 2005, Gelatinase-mediated migration and invasion of cancer cells, Biochim. Biophys. Acta, 1755, 37
  5. Yamakawa, 2004, (-)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis, Cancer Lett, 210, 47, 10.1016/j.canlet.2004.03.008 · DOI
  6. Annabi, 2009, Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling, Mol. Carcinog, 48, 910, 10.1002/mc.20541 · DOI
  7. Guo, 2013, Autophagy-mediated tumor promotion, Cell, 155, 1216, 10.1016/j.cell.2013.11.019 · DOI
  8. Ulasov, 2013, Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas, Cancer Med, 2, 457, 10.1002/cam4.104 · DOI · Paper page
  9. Currie, 2007, MT1-MMP down-regulates the glucose 6-phosphate transporter expression in marrow stromal cells: a molecular link between pro-MMP-2 activation, chemotaxis, and cell survival, J. Biol. Chem, 282, 8142, 10.1074/jbc.M610894200 · DOI
  10. Wu, 2006, Down-regulation of MT1-MMP expression suppresses tumor cell invasion in metastatic human SW626 ovarian cancer cells, Oncol. Rep, 15, 501
  11. Nandi, 2009, A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy, J. Gene Med, 11, 1005, 10.1002/jgm.1385 · DOI
  12. Brouwer, 2007, Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients, Cancer Gene Ther, 14, 211, 10.1038/sj.cgt.7701010 · DOI
  13. Li, 2012, A novel Ad5/11 chimeric oncolytic adenovirus for improved glioma therapy, Int. J. Oncol, 41, 2159, 10.3892/ijo.2012.1674 · DOI
  14. Zhu, 2005, Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo, Int. J. Oncol, 27, 237
  15. Leung, 2012, Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits Kaposi's sarcoma-associated herpesvirus replication and gene expression, Antimicrob. Agents Chemother, 56, 5794, 10.1128/AAC.01126-12 · DOI
  16. Wojton, 2010, Impact of tumor microenvironment on oncolytic viral therapy, Cytokine Growth Factor Rev, 21, 127, 10.1016/j.cytogfr.2010.02.014 · DOI
  17. Kang, 2008, Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus, Mol. Ther, 16, 1033, 10.1038/mt.2008.63 · DOI
  18. Chartier, 1996, Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli, J. Virol, 70, 4805, 10.1128/JVI.70.7.4805-4810.1996 · DOI
  19. He, 1998, A simplified system for generating recombinant adenoviruses, Proc. Natl. Acad. Sci. U.S.A., 95, 2509, 10.1073/pnas.95.5.2509 · DOI
  20. San Martin, 2008, Localization of the N-terminus of minor coat protein IIIa in the adenovirus capsid, J. Mol. Biol, 383, 923, 10.1016/j.jmb.2008.08.054 · DOI
  21. Heise, 2000, An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy, Nat. Med, 6, 1134, 10.1038/80474 · DOI
  22. Zhu, 2006, Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma, Int. J. Oncol, 29, 1319
  23. Ono, 2005, Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region, Cancer Res, 65, 10154, 10.1158/0008-5472.CAN-05-1871 · DOI
  24. Ulasov, 2015, Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy, Oncotarget, 28, 3977, 10.18632/oncotarget.2897 · DOI
  25. Raghu, 2010, Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines, PLoS ONE, 5, e12458, 10.1371/journal.pone.0012458 · DOI
  26. Ulasov, 2014, The emerging role of MMP14 in brain tumorigenesis and future therapeutics, Biochim. Biophys. Acta, 1846, 113
  27. Ulasov, 2009, Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy, Int. J. Oncol, 34, 729
  28. Pietrocola, 2013, Regulation of autophagy by stress-responsive transcription factors, Semin. Cancer Biol, 23, 310, 10.1016/j.semcancer.2013.05.008 · DOI
  29. Ryter, 2013, Autophagy: an integral component of the mammalian stress response, J. Biochem. Pharmacol. Res, 1, 176
  30. Hu, 2012, Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma, Cancer Res, 72, 1773, 10.1158/0008-5472.CAN-11-3831 · DOI
  31. Yang, 2011, The role of autophagy in cancer: therapeutic implications, Mol. Cancer Ther, 10, 1533, 10.1158/1535-7163.MCT-11-0047 · DOI
  32. Du, 2012, Role of autophagy in angiogenesis in aortic endothelial cells, Am. J. Physiol. Cell Physiol, 302, C383, 10.1152/ajpcell.00164.2011 · DOI
  33. Kunkle, 2013, Discovering gene-environment interactions in glioblastoma through a comprehensive data integration bioinformatics method, Neurotoxicology, 35, 1, 10.1016/j.neuro.2012.11.001 · DOI
  34. Devy, 2009, Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis, Cancer Res, 69, 1517, 10.1158/0008-5472.CAN-08-3255 · DOI
  35. Eisenach, 2010, MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src, J. Cell Sci, 123, 4182, 10.1242/jcs.062711 · DOI
  36. Sounni, 2002, MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression, FASEB J., 16, 555, 10.1096/fj.01-0790com · DOI
  37. Gabrusiewicz, 2011, Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas, PLoS ONE, 6, e23902, 10.1371/journal.pone.0023902 · DOI
  38. Trog, 2006, Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells, Eur. J. Pharmacol, 542, 8, 10.1016/j.ejphar.2006.05.026 · DOI
  39. Bancroft, 2001, Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways, Clin. Cancer Res, 7, 435
  40. Thaci, 2013, Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation, Gene Ther, 20, 318, 10.1038/gt.2012.42 · DOI
  41. Yoo, 2008, Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition, Gene Ther, 15, 635, 10.1038/gt.2008.3 · DOI
  42. Yoo, 2007, VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth, Mol. Ther, 15, 295, 10.1038/sj.mt.6300023 · DOI
  43. Saito, 2006, Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region, Cancer Gene Ther, 13, 242, 10.1038/sj.cgt.7700902 · DOI
  44. Zhou, 2003, E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model, Mol. Cancer Ther, 2, 1313
  45. Arbab, 2012, Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma, Histol. Histopathol, 27, 549

Cited by

Sorted by citations

Metadata

Authors
Ulasov, I., Borovjagin, A. V., Kaverina, N., Schroeder, B., Shah, N., Lin, B., Baryshnikov, A., & Cobbs, C.
ORCID
Ulasov, Ilya
Venue
Cancer Letters
Publisher
Elsevier BV
Published
2015-09
Volume
365
Issue
2
Pages
240-250
ISSN
0304-3835
DOI
10.1016/j.canlet.2015.06.002
Cited by
14
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • National Cancer Institute (R01 NS070289, R03 CA102031)
  • Russian Fund of Fundamental Research (11 411.0008700. 13.082, 13 411. 1008799.13.120)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review